Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

In comments to federal agency, PhRMA warns of the growing influence of middlemen over patient access and out-of-pocket costs for prescription medicines

By Brian Newell  |    May 31, 2022
In comments submitted to the Federal Trade Commission (FTC), PhRMA urged the agency to examine how pharmacy benefit managers (PBMs) leverage their extraordinary power to maximize profits, often in...   Read More

PhRMA presents research at ISPOR 2022

By Jackie McRae  |    May 26, 2022
Last week at the ISPOR annual international meeting, PhRMA partnered with multiple organizations committed to advancing value assessment research and methods. We worked with a range of academics,...   Read More

Report finds PBMs are increasingly restricting patient access to medicines

By Brian Newell  |    May 25, 2022
More than 1,150 medicines were excluded from at least one of the three largest PBMs’ standard commercial formularies in 2022, according to a new report from Xcenda. The report is further evidence of...   Read More

ICYMI: First pediatric patient to receive CAR-T cell therapy celebrates 10 years of being cancer-free

By Matthew Norawong  |    May 25, 2022
Recently, NBC News’ Today did a profile on one of the first pediatric patients in the world to receive a CAR-T cell therapy for the treatment of acute lymphoblastic leukemia (ALL). In April 2012, the...   Read More

Intellectual Property waiver on COVID-19 innovation is unnecessary and harmful

By Megan Van Etten  |    May 23, 2022
In two years, biopharmaceutical companies have gone from zero to 13 billion COVID-19 vaccine doses produced. They’ve worked across the industry and on every continent to meet the global demand for...   Read More

The time is now to address Brazil’s notorious patent backlog

By Anjam Aziz  |    May 20, 2022
It has been widely acknowledged that long patent examination delays cripple innovation, hinder economies, impede job creation and frustrate the launch of new products. Increased patent review times...   Read More

Study finds important health outcomes are not included in cost-effectiveness analyses for sickle cell, Alzheimer’s and MS treatments

By Katie Koziara  |    May 19, 2022
A new study from the Office of Health Economics (OHE) confirmed that the EQ-5D, a tool commonly used in health technology assessments (HTAs) often excludes outcomes important to patients and their...   Read More

Addressing social determinants of health to improve equitable access to medicines

By Jackie McRae  |    May 19, 2022
PhRMA Awards $150,000 to Address Social Determinants of Health:Announcing the Recipients of Round 4 of the PhRMA Collaborative Actions to Reach Equity (CAREs) Grant Program As part of PhRMA’s...   Read More

Gene therapies can reduce treatment burden and costs for patients with blood disorders

By Katie Koziara  |    May 18, 2022
A new analysis found potential gene therapies for blood disorders like hemophilia, beta thalassemia, and sickle cell disease hold promise in dramatically reducing existing treatment burdens for...   Read More

Report: More than 500 medicines in development to treat disorders of the blood

By Andrew Powaleny  |    May 18, 2022
Today, PhRMA released a new report covering 549 medicines in development to potentially treat disorders of the blood, including blood cancers. These conditions pose a significant and ongoing unmet...   Read More

A conversation with William Pao, Chief Development Officer of Pfizer

By Richard Moscicki, M.D.  |    May 17, 2022
Our industry continues working to build a more resilient, affordable and equitable health care system. I recently had the opportunity to connect with William Pao, M.D., Ph.D., Chief Development...   Read More

ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19

By Andrew Powaleny  |    May 13, 2022
This week, PhRMA sponsored The Washington Post’s event, Coronavirus: Lessons of the Pandemic, where PhRMA president and CEO Stephen J. Ubl shared crucial lessons learned from the pandemic on how to...   Read More

Why drug importation is bad for Americans

By Gabby Migliara  |    May 12, 2022
Drug importation schemes are dangerous and have significant negative consequences for both individuals and our health care system. Importation refers to when governments or individuals circumvent the...   Read More

Ensuring timely reauthorization of PDUFA and BsUFA

By Matthew Norawong  |    May 11, 2022
Today, the House Energy and Commerce Subcommittee on Health will be hosting a markup session on the comprehensive legislative package to reauthorize the human drug user fee programs, including the...   Read More

ICYMI: PhRMA COO Lori Reilly spotlights efforts to improve health care in 2022 and beyond

By Emilie Signora  |    May 9, 2022
The COVID-19 pandemic has made clear how important a stable health care system is to the American people, both during times of crisis and beyond. Patients deserve sustainable, patient-centered...   Read More

Spotlighting a growing mental health challenge

By Anne McDonald Pritchett, PhD  |    May 9, 2022
During the pandemic, about four in 10 American adults have reported symptoms of anxiety or depressive disorder. This share is up from one in 10 adults reporting symptoms prior to the pandemic....   Read More

Annual projections from NHE compared to actual health care spending

By Katie Koziara  |    May 5, 2022
The Centers for Medicare & Medicaid Services (CMS) recently released their National Health Expenditure (NHE) projections of health care spending in the United States through 2030. While these data...   Read More

Study finds insurance barriers disproportionately burden patients with chronic illness

By Cynthia Hicks  |    May 4, 2022
A recent Patient Experience Survey found that Americans with serious chronic conditions, including autoimmune diseases, mental health conditions and neurologic conditions were more likely than all...   Read More

A conversation with Barry Greene, CEO of Sage Therapeutics

By Stephen J. Ubl  |    May 4, 2022
Our industry continues working to build a more resilient, affordable and equitable health care system. As part of Mental Health Awareness Month, I recently had the opportunity to connect with PhRMA...   Read More

Innovative contracts continue to gain traction and improve quality of care

By Katie Koziara  |    May 2, 2022
Innovative contracts can help bring more value to patients and the health care system. These types of payment arrangements can include:   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates